Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United StatesGlobeNewsWire • 01/26/23
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney DiseaseGlobeNewsWire • 11/29/22
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31GlobeNewsWire • 10/24/22
KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of NephrologyGlobeNewsWire • 10/17/22
Renalytix to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care PhysiciansGlobeNewsWire • 08/08/22
Renalytix (RNLX) CEO, James McCullough on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 06/30/22
Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30GlobeNewsWire • 06/23/22
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease PatientsGlobeNewsWire • 06/10/22
KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient CohortGlobeNewsWire • 06/06/22
Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®GlobeNewsWire • 06/02/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renalytix Plc - RNLXPRNewsWire • 04/23/22
Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible BreakoutSeeking Alpha • 04/05/22
Renalytix Plc (RNLX) CEO James McCullough on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22